Overview

• Semaglutide was associated with a 42% lower one-year risk of hospitalization or death and tirzepatide with a 58% reduction versus sitagliptin.
• Researchers at Mass General Brigham analyzed 2018–2024 US insurance claims from more than 90,000 adults with HFpEF who were obese and had type 2 diabetes.
• Sitagliptin served as the active comparator to emulate a placebo group because it is not known to affect HFpEF outcomes.
• A head-to-head analysis involving about 28,100 patients found no meaningful advantage for tirzepatide over semaglutide.
• The findings were presented at the ESC Congress in Madrid and published in JAMA, and they remain observational rather than proof of efficacy.